TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 41, 2012, Pages 16618-16623

  Liu, Jieqiong ^a,b   Liao, Shan ^a   Diop Frimpong, Benjamin ^a   Chen, Wei ^a,b   Goel, Shom ^a   Naxerova, Kamila ^a   Ancukiewicz, Marek ^a   Boucher, Yves ^a   Jain, Rakesh K ^a   Xu, Lei ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast cancer; Drug delivery; Vessel normalization

Indexed keywords

1D11 NEUTRALIZING ANTIBODY; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 1; DOXORUBICIN; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN TYPE I; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867362497     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117610109     Document Type: Article

References (50)

1. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653-664.
2. Jain RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46:149-168.
3. Moses H, Barcellos-Hoff MH (2011) TGF-beta biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol 3:a003277.
4. Nam JS, et al. (2008) An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68:3835-3843.
5. Ehata S, et al. (2007) Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98:127-133. (Pubitemid 44803931)
6. Ehata S, et al. (2007) Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. Cancer Res 67:9694-9703. (Pubitemid 47621216)
7. Zhong Z, et al. (2010) Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16:1191-1205.
8. Muraoka RS, et al. (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109:1551-1559. \
9. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4:655-657.
10. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK (2011) Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Annu Rev Chem Biomol Eng 2:281-298.
11. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49:6449-6465. (Pubitemid 20008770)
12. Yuan F, Krol A, Tong S (2001) Available space and extracellular transport of macromolecules: Effects of pore size and connectedness. Ann Biomed Eng 29:1150-1158. (Pubitemid 34167829)
13. Choi J, et al. (2006) Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration. Clin Cancer Res 12:1906-1912.
14. Stylianopoulos T, et al. (2012) Growth-induced solid stress in murine and human tumors: Causes, consequences and remedies. Proc Natl Acad Sci USA 109:15101-15108.
15. Dentelli P, et al. (2004) IL-3 affects endothelial cell-mediated smooth muscle cell recruitment by increasing TGF beta activity: Potential role in tumor vessel stabilization. Oncogene 23:1681-1692. (Pubitemid 38445160)
16. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685-693.
17. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M (1995) PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 48:111-117.
18. Salnikov AV, et al. (2005) Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 85:512-521. (Pubitemid 40523943)
19. Cabral H, et al. (2011) Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6:815-823.
20. Kano MR, et al. (2007) Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 104:3460-3465. (Pubitemid 46364181)
21. Chauhan VP, et al. (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7:383-388.
22. Tong RT, et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736. (Pubitemid 38697278)
23. Gaengel K, Genové G, Armulik A, Betsholtz C (2009) Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29:630-638.
24. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417-427.
25. Goel S, et al. (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071-1121.
26. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62.
27. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK (2011) Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci USA 108:2909-2914.
28. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK (2000) Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 60:2497-2503. (Pubitemid 30262444)
29. Pluen A, et al. (2001) Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 98:4628-4633. (Pubitemid 32295027)
30. Brown E, et al. (2003) Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 9:796-800. (Pubitemid 36749232)
31. Au JL, Jang SH, Wientjes MG (2002) Clinical aspects of drug delivery to tumors. J Control Release 78:81-95. (Pubitemid 34081855)
32. Jakowlew SB (2006) Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25:435-457.
33. Saunier EF, Akhurst RJ (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6:565-578. (Pubitemid 44691000)
34. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ (2005) Proprotein convertases: "Master switches" in the regulation of tumor growth and progression. Mol Carcinog 44:151-161. (Pubitemid 41552748)
35. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A (2003) Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 162:439-447. (Pubitemid 36267851)
36. Dubois CM, et al. (2001) Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 158:305-316. (Pubitemid 32096497)
37. Leitlein J, et al. (2001) Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol 166:7238-7243. (Pubitemid 32525597)
38. Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hernández G, López-Casillas F (2001) Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem J 355:215-222. (Pubitemid 32304252)
39. Bandyopadhyay A, et al. (2002) Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21:3541-3551. (Pubitemid 34587686)
40. Bandyopadhyay A, et al. (2005) Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 63:81-90. (Pubitemid 40365392)
41. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT (2003) Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 44:3394-3401. (Pubitemid 36909776)
42. Sawyer JS, et al. (2003) Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 46:3953-3956. (Pubitemid 37122441)
43. Liao S, et al. (2011) TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res 17:1415-1424.
44. Lu S, Dong Z (2006) Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate 66:996-1004. (Pubitemid 43849597)
45. Wang Y, Yuan F (2006) Delivery of viral vectors to tumor cells: Extracellular transport, systemic distribution, and strategies for improvement. Ann Biomed Eng 34:114-127.
46. Monsky WL, et al. (1999) Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59:4129-4135. (Pubitemid 29393588)
47. McKee TD, et al. (2006) Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 66:2509-2513.
48. Sounni NE, et al. (2010) Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech 3:317-332.
49. Jang SH, Wientjes MG, Au JL (2001) Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: Effect of treatment schedule. J Pharmacol Exp Ther 296:1035-1042. (Pubitemid 32187379)
50. Grantab R, Sivananthan S, Tannock IF (2006) The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 66:1033-1039. (Pubitemid 43165971)